Summary

The rollout of dolutegravir as first-line ART has the potential to become another important step in the evolution of HIV treatment programmes in LMICs. The superior
durability of this INSTI should simplify treatment pathways and, when coupled with increasing viral load coverage, present an opportunity to focus on improving ART adherence and increasing levels of viral suppression. This research explores these opportunities.